Treatment Outcomes for Portal Hypertension Esophageal and Gastric Varices
ID: NCT07358663
Our intelligence engine has synthesized this trial record to answer your most important questions in clear, simple terms:
This study is a single-center, prospective cohort study based on real-world data. Patients with portal hypertension and esophagogastric varices were enrolled and divided into an endoscopic treatment group and a non-endoscopic treatment group (including patients receiving medical therapy, interventional procedures, or surgical treatment) according to whether they underwent endoscopic intervention. Baseline data, serum metabolites, CT imaging and endoscopic images, liver biopsy pathology, and other multi-omics data were integrated for both groups. Patients were followed up to compare adverse events after variceal treatment, including rebleeding and its causes, hepatic encephalopathy, ascites, subsequent treatments (such as regular endoscopic therapy, NSSB, and TIPS), and survival outcomes. Clinical characteristics of portal hypertension attributed to different etiologies, including hepatitis B, autoimmune liver disease, schistosomiasis, hematological disorders, and chemotherapy-induced liver injury, were compared. The efficacy and safety of endoscopic and interventional treatments for esophagogastric varices were evaluated. Factors influencing rebleeding rates among different treatment groups were analyzed, and reasons for inclusion in different groups were discussed.
Treatment Arms Description
Patients who receive endoscopic treatment
Patients who received alternative treatments (excluding endoscopic therapy)
- Clinical diagnosis of portal hypertension with esophagogastric varices.
- Underwent abdominal CT and gastroscopy examinations.
- Presence of peptic ulcer, gastric tumor, or other causes of gastrointestinal bleeding confirmed by imaging or gastroscopy.
- CT images of inadequate quality or incomplete medical history data.
Primary Outcome Measures
- Survival — Time Frame: At 1, 2, 6, and 12 months post-treatment
Survival status
View Secondary Outcome Measures (1)
- Adverse events — Time Frame: At 1, 2, 6, and 12 months post-treatment
Post-treatment adverse events included rebleeding (and its causes), hepatic encephalopathy, and ascites
This trial is recruiting at 1 study facilities worldwide. Click below to see if there is a clinic or hospital in your area:
Show All 1 Facilities & Contact Sites
Want to apply or inquire about joining this study? Fill out this simple questionnaire, and our assistant will instantly generate a professional email draft you can copy and send to the central contact coordinator listed above!
View Official Medical/Scientific Title
Assessment of Treatment Outcomes for Esophageal and Gastric Varices Secondary to Portal Hypertension